137 related articles for article (PubMed ID: 38110323)
21. A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer.
Huang Y; Lv SQ; Liu PY; Ye ZL; Yang H; Li LF; Zhu HL; Wang Y; Cui LZ; Jiang DQ; Hao FY; Xu HM; Jin HJ; Qian QJ
Mol Oncol; 2020 Mar; 14(3):657-668. PubMed ID: 31899582
[TBL] [Abstract][Full Text] [Related]
22. The role of cis dimerization of signal regulatory protein alpha (SIRPalpha) in binding to CD47.
Lee WY; Weber DA; Laur O; Stowell SR; McCall I; Andargachew R; Cummings RD; Parkos CA
J Biol Chem; 2010 Dec; 285(49):37953-63. PubMed ID: 20826801
[TBL] [Abstract][Full Text] [Related]
23. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
24. Neuronal signal-regulatory protein alpha drives microglial phagocytosis by limiting microglial interaction with CD47 in the retina.
Jiang D; Burger CA; Akhanov V; Liang JH; Mackin RD; Albrecht NE; Andrade P; Schafer DP; Samuel MA
Immunity; 2022 Dec; 55(12):2318-2335.e7. PubMed ID: 36379210
[TBL] [Abstract][Full Text] [Related]
25. Novel CD47: SIRPα dependent mechanism for the activation of STAT3 in antigen-presenting cell.
Toledano N; Gur-Wahnon D; Ben-Yehuda A; Rachmilewitz J
PLoS One; 2013; 8(9):e75595. PubMed ID: 24073274
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor effect of PTEN and its effect on inhibition of the bone tumor through the CD47-SIRPα signaling pathway.
Zhang Y; Hao J
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):40-44. PubMed ID: 38279488
[TBL] [Abstract][Full Text] [Related]
27. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
28. The CD47-SIRPα signalling system: its physiological roles and therapeutic application.
Murata Y; Kotani T; Ohnishi H; Matozaki T
J Biochem; 2014 Jun; 155(6):335-44. PubMed ID: 24627525
[TBL] [Abstract][Full Text] [Related]
29. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
Zhang J; Jin S; Guo X; Qian W
J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
[TBL] [Abstract][Full Text] [Related]
30. Surfactant protein D (Sp-D) binds to membrane-proximal domain (D3) of signal regulatory protein α (SIRPα), a site distant from binding domain of CD47, while also binding to analogous region on signal regulatory protein β (SIRPβ).
Fournier B; Andargachew R; Robin AZ; Laur O; Voelker DR; Lee WY; Weber D; Parkos CA
J Biol Chem; 2012 Jun; 287(23):19386-98. PubMed ID: 22511785
[TBL] [Abstract][Full Text] [Related]
31. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
Front Immunol; 2020; 11():18. PubMed ID: 32082311
[TBL] [Abstract][Full Text] [Related]
32. Macrophage-associated immune checkpoint CD47 blocking ameliorates endometriosis.
Li J; Yan S; Li Q; Huang Y; Ji M; Jiao X; Yuan M; Wang G
Mol Hum Reprod; 2022 Apr; 28(5):. PubMed ID: 35404426
[TBL] [Abstract][Full Text] [Related]
33. Biomimetic Design of Peptide Inhibitor to Block CD47/SIRPα Interactions.
Zheng S; Ji Y; Li N; Zhang L
Langmuir; 2023 Dec; 39(49):18101-18112. PubMed ID: 38038444
[TBL] [Abstract][Full Text] [Related]
34. Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy.
Chen H; Yang Y; Deng Y; Wei F; Zhao Q; Liu Y; Liu Z; Yu B; Huang Z
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110357
[TBL] [Abstract][Full Text] [Related]
35. CD47/SIRPα axis: bridging innate and adaptive immunity.
van Duijn A; Van der Burg SH; Scheeren FA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35831032
[TBL] [Abstract][Full Text] [Related]
36. Phylogenetic divergence of CD47 interactions with human signal regulatory protein alpha reveals locus of species specificity. Implications for the binding site.
Subramanian S; Boder ET; Discher DE
J Biol Chem; 2007 Jan; 282(3):1805-18. PubMed ID: 17098740
[TBL] [Abstract][Full Text] [Related]
37. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.
Chen J; Zhong MC; Guo H; Davidson D; Mishel S; Lu Y; Rhee I; Pérez-Quintero LA; Zhang S; Cruz-Munoz ME; Wu N; Vinh DC; Sinha M; Calderon V; Lowell CA; Danska JS; Veillette A
Nature; 2017 Apr; 544(7651):493-497. PubMed ID: 28424516
[TBL] [Abstract][Full Text] [Related]
38. Signal regulatory protein alpha (SIRPalpha)/CD47 interaction and function.
Barclay AN
Curr Opin Immunol; 2009 Feb; 21(1):47-52. PubMed ID: 19223164
[TBL] [Abstract][Full Text] [Related]
39. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
Veillette A; Chen J
Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
[TBL] [Abstract][Full Text] [Related]
40. CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies.
Bouwstra R; van Meerten T; Bremer E
Clin Transl Med; 2022 Aug; 12(8):e943. PubMed ID: 35908284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
